Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1 1

Status

Recruiting 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 1Nevus, Blue 1Melanoma 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × tebentafusp × Clear all
NCT06246149 2026-03-04

ATOM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
290 enrolled
Dermatologic

Uveal Melanoma

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡